{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:14Z","timestamp":1792786154641,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Wu Jieping Medical Foundation Special Fund for Clinical Research","award":["320.6750.2022-22-41"],"award-info":[{"award-number":["320.6750.2022-22-41"]}],"id":[{"id":"https:\/\/ror.org\/05dgwj702","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ningbo Clinical Research Center for thoracic & breast neoplasms","award":["2021L002"],"award-info":[{"award-number":["2021L002"]}]},{"name":"Ningbo Key Research and Development Program","award":["2024Z207"],"award-info":[{"award-number":["2024Z207"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,2]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Ambrisentan is an endothelin receptor antagonist broadly used for the treatment of pulmonary arterial hypertension. However, multiple adverse events (AEs) were reported with its use, and we intended to evaluate potential ambrisentan-associated AE signals through the US Food and Drug Administration Adverse Event Reporting System. Reports from March 2019 to December 2022 were selected for disproportionality analysis. Four signal detection methods were applied, namely the reporting odds ratio, the proportional reporting ratio, the information component, and the empirical Bayes geometric mean, to assess ambrisentan-associated AE signals. Ambrisentan was identified as a suspected drug in 30,060 reports. AEs associated with ambrisentan covered 8 system organ classes and showed potential signals at the preferred-term level, such as peripheral edema and dyspnea, as well as cardiac AE signals including palpitations and cardiac failure. The median time to onset of ambrisentan-associated AEs was 240 days, and approximately half (49.66%) of the AEs with documented time to onset occurred after 1 year of use. Our research identifies potential safety signals of cardiac AEs associated with ambrisentan use. These signals are hypothesis-generating and warrant confirmation in prospective studies, as well as continued pharmacovigilance monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050893","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:01:37Z","timestamp":1790967697000},"page":"e50893","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety assessment of ambrisentan based on the FDA Adverse Event Reporting System"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7868-7963","authenticated-orcid":false,"given":"Yanggang","family":"Dan","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261002","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension.","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R2-20261002","first-page":"73","article-title":"Pulmonary hypertension.","volume":"114","author":"Hoeper","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1750-1172-8-97","article-title":"Pulmonary arterial hypertension.","volume":"8","author":"Montani","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"j5492","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management.","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1753465817696040","article-title":"Ambrisentan: a review of its use in pulmonary arterial hypertension.","volume":"11","author":"Rivera-Lebron","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"15931","DOI":"10.1038\/s41598-020-72960-1","article-title":"Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis.","volume":"10","author":"Kappes","year":"2020","journal-title":"Sci Rep"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1517\/14656560903061275","article-title":"Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.","volume":"10","author":"Kingman","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ppul.22555","article-title":"Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.","volume":"48","author":"Takatsuki","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"R10-20261002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.","volume":"79","author":"Kuwana","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R11-20261002","doi-asserted-by":"crossref","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source.","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"R12-20261002","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200528010-00002","article-title":"Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions.","volume":"28","author":"Bousquet","year":"2005","journal-title":"Drug Saf"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.healun.2019.12.008","article-title":"Ambrisentan in portopulmonary hypertension: a multicenter, open-label trial.","volume":"39","author":"Preston","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"R15-20261002","first-page":"401","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes.","volume":"7","author":"Elshaboury","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"R16-20261002","doi-asserted-by":"crossref","first-page":"00","DOI":"10.3389\/fphar.2021.811700","article-title":"The transition from ambrisentan to macitentan in patients with pulmonary arterial hypertension: a real-word prospective study.","volume":"12","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"R17-20261002","doi-asserted-by":"crossref","first-page":"1712783","DOI":"10.3389\/fcvm.2026.1712783","article-title":"Disproportionality analysis of adverse events associated with endothelin receptor antagonists based on the FDA adverse event reporting system (FAERS).","volume":"13","author":"Han","year":"2026","journal-title":"Front Cardiovasc Med"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension.","volume":"46","author":"Galie","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R19-20261002","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin.","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol Rev"},{"key":"R20-20261002","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/01.CIR.0000109139.69775.EB","article-title":"Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention.","volume":"109","author":"Schirger","year":"2004","journal-title":"Circulation"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0735-1097(00)00822-6","article-title":"Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes.","volume":"36","author":"Araki","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R22-20261002","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/DDDT.S443107","article-title":"Understanding sorafenib-induced cardiovascular toxicity: mechanisms and treatment implications.","volume":"18","author":"Li","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"R23-20261002","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.lfs.2008.06.008","article-title":"The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species.","volume":"83","author":"De Giusti","year":"2008","journal-title":"Life Sci"},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/med.21280","article-title":"Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy.","volume":"34","author":"Carvalho","year":"2014","journal-title":"Med Res Rev"},{"key":"R25-20261002","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0008-6363(00)00263-7","article-title":"Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?","volume":"49","author":"Duru","year":"2001","journal-title":"Cardiovasc Res"},{"key":"R26-20261002","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40264-026-01677-3","article-title":"Theoretical framework and key considerations for time-to-onset analysis in spontaneous reporting systems.","volume":"49","author":"Noguchi","year":"2026","journal-title":"Drug Saf"},{"key":"R27-20261002","doi-asserted-by":"crossref","first-page":"e68938","DOI":"10.1371\/journal.pone.0068938","article-title":"The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance.","volume":"8","author":"Karimi","year":"2013","journal-title":"PLoS One"},{"key":"R28-20261002","doi-asserted-by":"crossref","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"R29-20261002","doi-asserted-by":"crossref","first-page":"2042098620938595","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future.","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"R30-20261002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1139\/cjpp-2024-0078","article-title":"Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database.","volume":"103","author":"Han","year":"2025","journal-title":"Can J Physiol Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:01:40Z","timestamp":1790967700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":30,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050893","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"2024-09-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}